We studied the effect of troglitazone on cellular acid-base balance and alanine formation in isolated rat mesangial cells. Mesangial cells were grown to confluency in RPMI 1640 media on 30mm chambers used to monitor both cellular pH using the pH-sensitive dye 2'7'-bis (2-carboxyethyl)-5,6-carboxyfluorescein and metabolic acid production as well as glutamine metabolism. Troglitazone (10µM) induced a spontaneous cellular acidosis (6.95±0.02 vs. 7.47±0.04 respectively, p<0.0001) but without an increase in lactic acid production. Alanine production was reduced 64% (p<0.01) consistent with inhibition of the glutamate transamination. These findings pointed to a decrease in acid extrusion rather than an increase in acid production as the underlying 
Introduction
Troglitazone is a peroxisome proliferator-activated receptor gamma, PPARγ, agonists (11) that exhibits insulin-sensitizing activity and attenuates hyperinsulinemia and hyperglycemia in humans with type 2 diabetes mellitus (9) .
Apart from the recognized effects of troglitazone on glucose metabolism, we have shown troglitazone to inhibit glutamate transamination and alanine formation while increasing ammonium formation in rat mesangial cells (29) .
Because acidosis has a similar effect on glutamate metabolism (33) , the question arises as to whether troglitazone induces a cellular acidosis and, if so, could this be an early and important parameter in subsequent troglitazone effects. Cell pH is an important signal for numerous cellular processes including glycolysis (8) and glutamine metabolism (23, 32) . Potential sites through which troglitazone might influence cellular acid-base balance are depicted in Figure 1 . Since pH i is a balance between net metabolic acid production and net acid extrusion (2, 4) , any effect of troglitazone on either of these two limbs of the balance could result in an alteration in cellular pH i and hence cell function. In this regard, we (29) as well as others (12) have shown that troglitazone enhances glucose uptake which is coupled to increased lactate formation and therefore enhanced acid production (8) . Indeed, in our previous metabolic study (29) the media bicarbonate concentration was inversely related to lactate concentration suggesting that metabolic acid production is largely, if not entirely, attributable to anaerobic glycolysis.
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Mesangial cells express both a sodium/hydrogen ion exchanger as well as a bicarbonate activated acid-extruding transporter (5, 14) as shown in Figure   1 . Because the exchanger activity is allosterically modulated by an increase in cytosolic hydrogen ion concentration (3) , an increase in acid production and a fall in pH i should upregulate the rate of acid extrusion. As a consequence, the decrease in pH i would be far less than that that predicted based solely on increased acid production. On the other hand, if troglitazone inhibits either one or both of the acid extruding mechanism while increasing metabolic acid production then the resulting drop in pH i is likely to be severe and physiologically significant, that is, have effects on glutamine metabolism and cellular processes.
To test whether troglitazone would in fact induce a cellular acidosis, we loaded mesangial cells with the fluorescent pH indicator 2'7'-bis (2-carboxyethyl)-5,6-carboxyfluorescein (BCECF) and exposed them to troglitazone over a period sufficient to monitor both the above metabolic end products as well as pH i . In addition, we assessed the ability of mesangial cells to extrude acid following an exogenous acid load. The results to follow show that troglitazone produces a profound cellular acidosis without increasing acid production but with a marked inhibition of the acid extrusion.
Material and Methods
Glomerular mesangial cells were obtained from Sprague-Dawley rat kidney glomeruli isolated by differential sieving as previously described (28 Experimental Design. In order to observe the pH i response to troglitazone under the conditions previously used for mesangial cell metabolic studies (29) monolayers were initially studied in RPMI 1640 media. After a 0.5h control period over which pH i and lactate and alanine formation were monitored, the media was replaced with RPMI 1640 containing troglitazone and the acid production and alanine formation associated with the change in pH i again determined.
Comparisons were then made between control and troglitazone treatment differences in pH i , acid production and glutamine metabolism using the Student ttest. Acid production was estimated from the change in media lactate content measured over the 0.5h incubation period; change in alanine formation was
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taken as an index of inhibition of the transamination pathway as previously demonstrated (29, 33) . The concentration of lactate and alanine in the media were measured by enzymatic and HPLC methods as previously described (23) and expressed per mg protein. repetitive acid load were also performed establishing that the recovery rates were not different for the loading periods. Differences between the control pre-load pH i and pH i measured at 1, 4, and 8 minutes of recovery were analyzed using ANOVA and a corrected Student t-test (Bonnferoni) while differences within the recovery periods between control and troglitazone ∆pH i /min responses were determined using a paired Students t-test. When appropriate, based on the a priori hypotheses presented in Figure 1 , a one-tailed t-table was consulted;
otherwise a 2-tailed t-test was used. Figure 3B shows that this cellular acidosis develops without a detectable increase in lactate production (17±2 and 15±3nmol/min/mg protein for control and 10µM troglitazone respectively) indicating that increased metabolic acid production is not responsible for the cellular acidosis. However as shown in Figure 3C , troglitazone treatment reduced alanine production by 64% (325±32 to 117±32 pmol/min/mg protein, p<0.001) consistent with inhibition of the transamination pathway (29) and reduced glutamine metabolism (33).
Results
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Because the therapeutic plasma concentration range for troglitazone is 5-15µM (9), we studied the steady-state cell pH measured after 30 minutes incubation in the RPMI media containing 17% fetal calf serum in response to 5, 10, and 20µM troglitazone (glitazones may bind to plasma proteins,9, and therefore studies in which they are excluded may not reflect the in vivo conditions). As shown in (Figure 1) . For the overall 8 minute recovery period, the ∆pH i /min fell from 0.06±0.02 to 0±0.01(p<0.0001). In the HEPES buffered media, which limits the response to the NHE alone, the response to 10µM troglitazone was also to reduce acid extrusion but less than that occurring 
The presence of 2mM glutamine added to the HEPES media accelerated the recovery response to the acid load as shown in Figure 7 . After the first pulse in media with D-glucose as the only substrate, HEPES with 2mM L-glutamine was used in the subsequent recovery periods. As can be seen, the recovery was approximately twice as fast measured over the first 4minutes(0.09±0.02 vs 0.5±0.01∆pH i /min, N=4, p<0.05) in the presence of glutamine in agreement with the previous study (26) . However with 10uM troglitazone added to the HEPES + 2mM L-glutamine media, the recovery response was markedly reduced (0.01±0.01∆pH i /min, p<0.05). These results show that glutamine accelerates the NHE response to an acid load and troglitazone inhibits this glutamine enhanced acid extrusion as well.
Discussion
Our purpose was to determine if troglitazone would produce a cellular acidosis in rat mesangial cells and, if so, whether this effect could be attributed to either an increase in acid production or a decrease in acid extrusion, or, to both mechanisms. To estimate intracellular pH we utilized the fluorescent dye BCECF whose excitation at 490nm is directly related to the ambient pH while excitation at its isosbestic excitation wavelength, 440nm, provides an index of the BCECF present inside the cell (24) . The ratios obtained under high potassium and nigericin "clamp" conditions were directly related to pH i consistent with these ratios providing an estimate of the pH i under the conditions of our experimental protocol (data not shown). The BCECF intracellular distribution is cytosolic (5, 24) which is the cellular compartment most relevant to modulation of functional glutaminase and resulting glutamate metabolism (18, 27) . Because we utilized each monolayer as its own control, our results are reflective of the change in pH i rather than a "true" physiological pH i , which may or may not be determined by this technique (24) . Nevertheless the BCECF-estimated control pH i values in Krebs-Henseleit media approximated those previously obtained from mesangial cells incubated in a physiological saline media containing bicarbonate (5).
Similarly, we observed a significantly lower pH i in cells incubated in HEPES buffered Krebs-Henseleit media in agreement with the HEPES buffered saline in the previous studies (5, 14) . The higher pH estimate in bicarbonate containing media can be attributed to the operation of both the sodium/hydrogen ion exchanger as well as the bicarbonate-activated acid extruder (5). The higher pH i in RPMI media may reflect the presence of 2mM L-glutamine, which enhances the NHE activity associated with glutamate metabolism via the transamination pathway in vivo and in an intestinal cell line (1,26) and appears to play a similar role in acid extrusion from mesangial cells (Figure 7) . Interestingly, this action of glutamine can be blocked by eliminating the transamination pathway (26) , an effect on glutamine metabolism also exerted by troglitazone (29, 33) .
Why expect troglitazone to elicit a cellular acidosis? Our previous studies
showed that troglitazone markedly inhibited glutamate transamination (29, 33) and shifted the glutamate formed in the cytosol and utilized by the alanine aminotransferase pathway (20, 23) into the glutamate dehydrogenase pathway (19, 27) , the glutamate formed would either undergo transamination forming alanine or be transported into the mitochondrial matrix and undergo deamination forming ammonium. Consequently the fall in alanine formation ( Figure 3C ) and the increase in ammonium formation as previously shown (29, 33) support and, in turn, may be explained by the drop in pH i actually observed (Figures 2,3A and 4) .
Does the cellular acidosis result from increased acid production or decreased acid extrusion?
We (29) and others (12) had shown that troglitazone increases glucose uptake and lactate production suggesting that an increase in metabolic acid production could contribute to the troglitazone-induced cellular acidosis. By measuring simultaneously both the lactate production and the cell pH a comparison of the metabolic acid production over 30 minutes to the fall in cell pH was obtained. These results showed that a marked cellular acidosis develops without an increase in lactic acid production ( Figures 3A and B) . Of course, we can not rule out an early increase in acid production that subsequently becomes inhibited by the sharper fall in pH i ( Figure 2) ; however, this drop in pH i maintained at least over 30 minutes would be unusual if it was driven by increased acid production alone because of the activation of the acid extrusion systems by a similar fall in pH i induced by an exogenous acid load (Table 1 ) so that this impaired acid extrusion combined with the endogenous acid production suffices to account for the severe spontaneous cellular acidosis actually observed (Figure 2) .
Which acid extrusion system is inhibited by troglitazone? Mesangial cells
utilize both the sodium/hydrogen ion exchanger and the bicarbonate-activated acid extruder for transporting acid out of mesangial cells (5, 6, 14) as depicted in Figure 1 . Therefore we designed experiments to include both bicarbonate activated as well as the sodium/hydrogen ion exchanger. Under physiological conditions both systems should engage to handle an acid load, either that metabolically generated or as an exogenous NH 4 + load. In contrast only the sodium/hydrogen ion exchanger would operate in the HEPES buffered media.
Therefore we deployed media containing bicarbonate and minus bicarbonate in order to discern which of these two systems was the major site of inhibition. We challenged these cells with a standard 20mM NH 4 + load (4,5) for 4 minutes and monitored the acid extrusion response in the two different buffer systems.
Although the acid load was identical under both conditions, the acid extrusion response was nearly twice as fast in the bicarbonate as in the HEPES buffered media ( Table 1) as expected from the presence of the dual systems depicted in Figure 1 . Given these two potential sites of inhibition, one might expect a slowing of the response in the bicarbonate media and the elimination of the response in the HEPES buffered media if the sodium/hydrogen ion exchanger(s) was the sole site of inhibition. Alternately one of these systems might compensate in response to a lower pH i so that acid extrusion would only momentarily be slowed.
Surprisingly, troglitazone markedly inhibited the acid recovery response in both conditions, Table 1 . In fact over the first 4 minutes when the recovery response was inhibited by 73% in the bicarbonate buffer, the response in the HEPES was reduced only 49%; after 4 minutes the recovery response was virtually eliminated in both the bicarbonate and HEPES buffered media. These findings point to a greater sensitivity of the bicarbonate activated acid extrusion system than the sodium/hydrogen ion exchanger to troglitazone's action (10) . Nevertheless bladder urine obtained at the time of sacrifice and assayed for creatinine, protein and ammonium as described (16, 26 ) . Results are means ± SEM from 12 animals per group; asterisk indicates p<0.001 vs control lean group. Figure 8A shows that protein excretion factored by creatinine excretion was increased above control in the untreated diabetic animals and reduced to control level in diabetic animals treated with troglitazone. Figure 8B shows ammonium excretion factored by creatinine excretion by the same animals with ammonium excretion increased above the untreated diabetic animals and control groups in the troglitazone treated group. 
